TGTXbenzinga

TG Therapeutics Expects Full Year 2025 Revenue Of Approximately $540M Versus Consensus Of $548.20M, Including Briumvi U.S. Net Product Revenue Of Approximately $525M

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on March 3, 2025 by benzinga